恆達科技(01725.HK)易主後股價續飆58%曾見24.9元屢創紀錄高
2018年8月才以每股1.75元來港上市的內地電子製造服務(EMS)供應商--恆達科技(01725.HK),其63.75%股權易主香港航天科技集團兼提全購後,股價繼昨天復牌飆升3.2倍創紀錄高後,今天進一步升破昨天盤中所創高位17.5元,最高見24.9元,現造24.8元,續漲58%,成交313萬股,涉資7,088萬元。
香港航天科技集團主要從事衛星製造、衛星發射、航天測控及航天數據服務,彌補航天產業區域商業空白,推動航天技術市場化,服務區域航天商業化需求及投資控股。不過,要約人現時正在推進其要約人業務開發,尚未開展衛星製造業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.